DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Gallium (IV)

Phase Two

Phase Two

Therapeutic Approach

Anti-Infective

Gallium is a molecule, nearly identical to iron, that disrupts iron-dependent biological processes and has been shown to kill antibiotic-resistant strains of Pseudomonas aeruginosa in laboratory research. Gallium has already been approved by the FDA for intravenous use in people and is now being studied for its safety and effectiveness in controlling P. aeruginosa in people with CF.

Status

 A phase 2 trial is underway.

Sponsor

This program is sponsored by the Cystic Fibrosis Foundation Therapeutics and is being conducted within CFFT's Therapeutics Development Network.

Contact us about Gallium (IV) >